Enable Biosciences develops a predictive testing platform utilizing antibody detection methods for the early identification of Type 1 Diabetes. Their technology enhances risk prediction accuracy, enabling proactive management of the disease before clinical onset.
Funding
Funding not disclosed
Founders
Product
Problem
Early detection of Type 1 Diabetes (T1D) relies on identifying specific autoantibodies, but current testing methods may lack the sensitivity and accuracy needed for reliable risk prediction before clinical symptoms appear. This can lead to delayed intervention and management of the disease.
Solution
Enable Biosciences offers a predictive testing platform that utilizes a proprietary antibody detection method to improve the early identification of Type 1 Diabetes. Their technology enhances the accuracy of risk prediction by employing advanced screening methods, enabling proactive management of the disease before the onset of clinical symptoms. The platform aims to provide best-in-class T1D autoantibody tests, facilitating timely intervention and improved patient outcomes.
Target Audience
The primary audience includes healthcare providers, clinicians, and researchers involved in diabetes care, as well as individuals at risk of developing Type 1 Diabetes.
Features
- Advanced antibody detection method for improved sensitivity and specificity in T1D risk prediction.
- Predictive testing platform designed for early identification of T1D before clinical onset.
- Technology spun out of UC Berkeley and Stanford, with partnerships including Stanford Healthcare and Harvard Medical School.
- Over 150,000 tests performed, demonstrating experience in predictive medicine.